KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aurinia Pharmaceuticals (AUPH) Gross Margin (2021 - 2025)

Historic Gross Margin for Aurinia Pharmaceuticals (AUPH) over the last 6 years, with Q3 2025 value amounting to 88.87%.

  • Aurinia Pharmaceuticals' Gross Margin fell 22300.0% to 88.87% in Q3 2025 from the same period last year, while for Sep 2025 it was 88.93%, marking a year-over-year increase of 16800.0%. This contributed to the annual value of 87.99% for FY2024, which is 39500.0% down from last year.
  • Aurinia Pharmaceuticals' Gross Margin amounted to 88.87% in Q3 2025, which was down 22300.0% from 89.84% recorded in Q2 2025.
  • Over the past 5 years, Aurinia Pharmaceuticals' Gross Margin peaked at 98.82% during Q1 2022, and registered a low of 84.42% during Q2 2024.
  • In the last 5 years, Aurinia Pharmaceuticals' Gross Margin had a median value of 94.33% in 2022 and averaged 92.46%.
  • As far as peak fluctuations go, Aurinia Pharmaceuticals' Gross Margin crashed by -141900bps in 2024, and later soared by 54100bps in 2025.
  • Aurinia Pharmaceuticals' Gross Margin (Quarter) stood at 97.94% in 2021, then fell by -3bps to 95.21% in 2022, then decreased by -8bps to 88.04% in 2023, then increased by 3bps to 90.73% in 2024, then dropped by -2bps to 88.87% in 2025.
  • Its last three reported values are 88.87% in Q3 2025, 89.84% for Q2 2025, and 86.27% during Q1 2025.